Back to results
US 7,262,204 B2Granted
Modulation of CCR4 function
AssigneesAmgen Inc., ChemoCentryx, Inc.
InventorsTassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
Life of this patent
Estimating the term…
Abstract
Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
Claims18
A method for treating a disease or condition selected from asthma, atopic dermatitis, atherosclerosis, multiple sclerosis, rheumatoid arthritis and HIV infection in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein
- W is naphthyl;
- X is S;
- Y is NH;
- Z is N;
- R1 and R2 are independently selected from H, halogen, CN, CO2R′, CONR′R″ and (C1-C8)alkyl, wherein R′ and R″ are independently selected from H, (C1-C8)alkyl and aryl, and when R′ and R″ are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
3 more elements
Dependencies are inferred from the claim text.